ClinicalTrials.gg

Program

rentosertib

Also written as “INS018_055” and “INS018_055 tablets”.

Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by InSilico Medicine Hong Kong.

Furthest: phase 3, since Jun 22, 20264 company-led studies, 2 open or runningNext primary completion: Oct 30, 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
InSilico Medicine Hong Kong42 open or runningphase 3since Jun 22, 2026Nov 17, 2021Oct 30, 2029phase 3 · NCT07687459

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 17, 2021First study: phase 1 study in Idiopathic Pulmonary FibrosisFirst studyNCT05154240 · 78 enrolled · New Zealand
  2. Jun 28, 2023Phase 2 study in Idiopathic Pulmonary FibrosisNCT05938920 · 71 enrolled · China
  3. Jul 27, 2023Phase 2 study in Idiopathic Pulmonary FibrosisNCT05975983 · 40 planned · United States
  4. Jun 22, 2026Phase 3 study in Idiopathic Pulmonary FibrosisPhase 3 reachedNCT07687459 · 320 planned · China

Ahead

  1. Oct 30, 2029Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisNCT07687459

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07687459Idiopathic Pulmonary Fibrosis · China3RecruitingOct 30, 2029320
NCT05975983Idiopathic Pulmonary Fibrosis · United States2RecruitingFeb 28, 202640
NCT05938920Idiopathic Pulmonary Fibrosis · China2CompletedAug 8, 202471
NCT05154240Idiopathic Pulmonary Fibrosis · New Zealand1CompletedDec 2, 202278

How it is read

Names in the registry

  • “INS018_055”, 3 entries
  • “INS018_055 tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.